

Impact of Microstructural Properties on Drug Release from PLGA Microspheres

Ruifeng Wang¹, Andrew G. Clark², Quanying Bao¹, Yan Wang³, Bin Qin³, Shawn Zhang², Diane J. Burgess¹

¹ University of Connecticut, School of Pharmacy, Storrs, CT 06269, USA


² DigiM Solution LLC, 500 West Cummings Park, Suite 3650, Woburn, MA 01801, USA

³ Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA


Contact Information: ruifeng.2.wang@uconn.edu; d.burgess@uconn.edu

Introduction

- In the development of complex generic products such as poly (lactic-co-glycolic acid) (PLGA)-based microspheres, qualitative (Q1) and quantitative (Q2) sameness may not be sufficient to achieve comparable product performance as formulation characteristics are manufacturing dependent. This warrants special attention on similarity in microstructure (Q3).
- The Q3 properties can affect drug release and consequently, the efficacy and safety. The objective of this work was to investigate the relationship between microstructure and the release characteristics of microspheres using focused ion beam scanning electron microscopy (FIB-SEM) and quantitative artificial intelligence (AI)-based image analytics.



Methods




Results

Physicochemical properties of the prepared microspheres


Table 1. Drug loading and size of minocycline hydrochloride microspheres prepared with different processing parameters. All data are presented as mean ± SD (n=3).

	Stirring rate (rpm)	Silicone oil viscosity (cSt)	Drug Loading (% w/w)	Particle Size (D ₅₀ , Volume, μm)	Particle Size (D ₅₀ , Number, μm)
FA	350	350	26.18 ± 0.31	74.01±1.81	56.10±0.43
FB	350	1000	26.17 ± 0.14	62.34±0.39	48.03±0.18
FC	600	350	26.37 ± 0.27	72.47±0.81	54.12±0.16
FD	600	1000	26.41 ± 0.47	57.56±0.40	41.43±0.36

In vitro release characteristics




- In vitro release profiles of the prepared microspheres using the sample-and-separate method. All data are presented as mean ± SD (n=3). The release profiles were analyzed using the first order model.




Correlation


	Polymer ratio (%) in 35% outer layer	k_1
FA	53.42	0.1522
FB	49.49	0.392
FC	61.90	0.0847
FD	51.82	0.3243



Morphology and representative FIB-SEM images




In vitro degradation




- SEM cross-sectional images of the prepared microsphere formulations incubated in release medium at day 6. The green arrows point to the remaining drug particles inside the microspheres. The ratio of R_1/R_2 is 35%.


Representative 3D reconstruction and microstructure analysis



Size distribution of API and pores



3D volume fractions of different phases



- Upon contact with the release medium, PLGA is degraded into shorter chain acids. An accumulation of the degradation products can lead to local pH decrease and consequently an autocatalytic effect, resulting in accelerated heterogenous degradation of PLGA.

Conclusions

- Microstructural properties (e.g., volume fraction and spatial distribution of polymer, drug, and pores) of four in-house microsphere formulations were determined using FIB-SEM.
- Internal phase fractions and phase spatial distributions were identified that related to the release performance. The release rate was correlated with the polymer content in the outer layer.
- The established correlation between microstructural properties and release characteristics can potentially support a more robust understanding of the impact of the microstructure properties on the release mechanisms of microspheres, and facilitate the establishment of Q3 equivalence of two products.

References

Ruifeng, W., Quanying, B., Andrew G., et al. *Int. J. of Pharm.* 628, 122292.
Andrew G., C., Ruifeng, W., Yuri, Q., et al. *J. Control. Release.* 349, 580-591.
Jie, S., & Diane J., B. J. *Pharm. Pharmacol.* 64(7), 986–996.

Acknowledgments and Disclaimer

- Funding for this project was provided by the U.S. Food and Drug Administration through the Contract #75F40119C10157. The content reflects the views of the authors and should not be construed to represent FDA's views or policies.

UConn
SCHOOL OF PHARMACY

